These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 34948399)
1. A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. Uribe KB; Chemello K; Larrea-Sebal A; Benito-Vicente A; Galicia-Garcia U; Bourane S; Jaafar AK; Lambert G; Martín C Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948399 [TBL] [Abstract][Full Text] [Related]
2. Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. Di Taranto MD; Benito-Vicente A; Giacobbe C; Uribe KB; Rubba P; Etxebarria A; Guardamagna O; Gentile M; Martín C; Fortunato G Sci Rep; 2017 Nov; 7(1):15282. PubMed ID: 29127338 [TBL] [Abstract][Full Text] [Related]
3. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Sánchez-Hernández RM; Di Taranto MD; Benito-Vicente A; Uribe KB; Lamiquiz-Moneo I; Larrea-Sebal A; Jebari S; Galicia-Garcia U; Nóvoa FJ; Boronat M; Wägner AM; Civeira F; Martín C; Fortunato G Atherosclerosis; 2019 Oct; 289():162-172. PubMed ID: 31518966 [TBL] [Abstract][Full Text] [Related]
4. Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject. Larrea-Sebal A; Trenti C; Jebari-Benslaiman S; Bertolini S; Calandra S; Negri EA; Bonelli E; Benito-Vicente A; Uraga-Gracianteparaluceta L; Martín C; Fasano T Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834740 [TBL] [Abstract][Full Text] [Related]
5. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992 [TBL] [Abstract][Full Text] [Related]
6. Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia. Benito-Vicente A; Uribe KB; Larrea-Sebal A; Palacios L; Cenarro A; Calle X; Galicia-Garcia U; Jebari-Benslaiman S; Sánchez-Hernández RM; Stef M; Lambert G; Civeira F; Martín C Arterioscler Thromb Vasc Biol; 2022 Jul; 42(7):e203-e216. PubMed ID: 35510551 [TBL] [Abstract][Full Text] [Related]
7. Patients With Doi T; Hori M; Harada-Shiba M; Kataoka Y; Onozuka D; Nishimura K; Nishikawa R; Tsuda K; Ogura M; Son C; Miyamoto Y; Noguchi T; Shimokawa H; Yasuda S J Am Heart Assoc; 2021 Feb; 10(4):e018263. PubMed ID: 33533259 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120 [TBL] [Abstract][Full Text] [Related]
10. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731 [TBL] [Abstract][Full Text] [Related]
11. Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia. Darabi M; Lhomme M; Ponnaiah M; Pučić-Baković M; Guillas I; Frisdal E; Bittar R; Croyal M; Matheron-Duriez L; Poupel L; Bonnefont-Rousselot D; Frere C; Varret M; Krempf M; Cariou B; Lauc G; Guerin M; Carrie A; Bruckert E; Giral P; Le Goff W; Kontush A J Clin Lipidol; 2023; 17(5):643-658. PubMed ID: 37550151 [TBL] [Abstract][Full Text] [Related]
12. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin. Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778 [TBL] [Abstract][Full Text] [Related]
14. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741 [TBL] [Abstract][Full Text] [Related]
15. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. Poirier S; Hamouda HA; Villeneuve L; Demers A; Mayer G PLoS One; 2016; 11(6):e0157230. PubMed ID: 27280970 [TBL] [Abstract][Full Text] [Related]
16. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA. Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977 [TBL] [Abstract][Full Text] [Related]
17. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor). Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664 [TBL] [Abstract][Full Text] [Related]
18. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079 [TBL] [Abstract][Full Text] [Related]
19. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles. Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048 [TBL] [Abstract][Full Text] [Related]
20. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]